Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Other studies focused on bladder cancer, prostate cancer and liquid biopsies.
Overall survival was 14.4 months for HR+/HER2- patients who received sacituzumab govitecan versus 11.2 months for those given chemotherapy.
The antibody-drug conjugate is now approved for patients with hormone receptor-positive/HER2-negative or triple-negative breast cancer.
Patients treated with Trodelvy had a 21% reduction in the risk for death.
Treatment-experienced people who received the antibody-drug conjugate lived three months longer than those who got more chemotherapy.
People who received the antibody-drug conjugate were also more likely to experience tumor remission.
The antibody-drug conjugate shrank tumors in 28% of people with locally advanced or metastatic urothelial cancer.
The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.
The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.